Product Description
The M2T™ program is a recombinant protein-based immunotherapy platform that delivers antigens directly to MHCII molecules on antigen-presenting cells. This boosts presentation to the immune system, overcomes immune tolerance, and generates a powerful B and T cell response against the chosen antigen. M2T-CD33 is our lead clinical candidate for first-in-man studies in Acute Myelogenous Leukemia (AML) and other hematology/oncology indications. M2T-mesothelin is our second development candidate for pancreatic cancer. In addition, we are developing other candidates for some of the deadliest cancers, which are in need of new and effective therapies. (Sourced from: https://leukogene.com/pipeline/)
Mechanisms of Action: CD33 Inhibitor
Novel Mechanism: No
Modality: Unknown
Route of Administration: N/A
FDA Designation: Orphan Drug - Acute Myeloid Leukemia *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Leukogene
Company Location:
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 0: Acute Myeloid Leukemia
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|